<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107442">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01715363</url>
  </required_header>
  <id_info>
    <org_study_id>2011-003446-41</org_study_id>
    <secondary_id>2010/1676</secondary_id>
    <nct_id>NCT01715363</nct_id>
  </id_info>
  <brief_title>Feasibility of an Immediate Preoperative Chemotherapy Before Resection fo Colorectal Cancer</brief_title>
  <acronym>PRIMM</acronym>
  <official_title>Feasibility of an Immediate Preoperative Chemotherapy Before Resection of Colorectal Cancer and Research of Gene Expressions Changes Induced in the Tumor, Predictive of Chemotherapy Efficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyze the clinical tolerance of immediate preoperative
      chemotherapy in terms of toxicity and perioperative morbidity and mortality
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical tolerance of immediate preoperative chemotherapy</measure>
    <time_frame>Assess up to 30 days after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical tolerance of immediate preoperative chemotherapy assessment is based on the post-operative complication rate in terms of morbidity and mortality.
All the post-operative complications arising within 30 days after surgery will be registered and classified using the Clavien Dindo classification</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Patients With Colorectal Cancer With Unresectable Synchronous Metastasis in Whom Resection of the Primitive Tumour is Indicated</condition>
  <arm_group>
    <arm_group_label>FOLFOX + surgery + FOLFOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Systemic chemotherapy (modified FOLFOX 4) 48 hours before surgery
resection of the colorectal tumor during surgery
Resumption of FOLFOX within the month after surgery (post operative administration of 4 course of treatment and assessment of the response)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>FOLFOX + surgery + FOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <arm_group_label>FOLFOX + surgery + FOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracile</intervention_name>
    <arm_group_label>FOLFOX + surgery + FOLFOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  colorectal metastatic adenocarcinoma (stage IV) with unresectables, measurables and
             visibles secondary lesions

          -  primitive tumor must be operate

          -  patient age between 18 and 70

          -  OMS status performance &lt; 2

          -  life expectancy &gt; 12 weeks

          -  hematologic function : PNN &gt;/= 1.5x10^9/L, platelets &gt;/= 100x10^9/L

          -  hepatic function : bilirubin &lt;/= 1.5xLSN, AST and ALT &lt;/= 3xLSN, alcalin phosphatasis
             &lt;/= 3xLSN

          -  plasmatimic creatin &lt;/= 1.25xLSN

          -  No previous chemotherapy or pelvic radiotherapy

          -  men and women in age of procreate agreeing  to use a contraception until 4 months
             after the end of treatment for women and until 6 months for men

        Exclusion Criteria:

          -  nonmetastatic forms

          -  Colorectal tumor which requires preoperative radiotherapy

          -  nonmeasurable metastasis based on RECIST criteria

          -  previous chemotherapy for colorectal cancer

          -  previous irradiation of the primitive tumour

          -  specific indication against the treatment studied

          -  Patient considered as inoperable for physiological or carcinologic reasons

          -  Pregnant or breast feeding women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diane GOERE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diane GOERE, MD</last_name>
    <phone>+33 1 42 11 54 41</phone>
    <email>diane.goere@igr.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie BOIGE, MD</last_name>
    <phone>+33 1 42 11 43 11</phone>
    <email>valerie.boige@igr.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val de Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane GOERE, MD</last_name>
      <phone>+33 1 42 11 54 41</phone>
      <email>diane.goere@igr.fr</email>
    </contact>
    <investigator>
      <last_name>Diane GOERE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 25, 2012</lastchanged_date>
  <firstreceived_date>October 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
